DNAGinkgo Bioworks Holdings, Inc.

NYSE ginkgobioworks.com


$ 0.70 $ -0.03 (-4.14 %)    

Wednesday, 22-May-2024 15:59:53 EDT
QQQ $ 454.82 $ -0.09 (-0.02 %)
DIA $ 398.57 $ -2.12 (-0.53 %)
SPY $ 530.36 $ -1.53 (-0.29 %)
TLT $ 91.26 $ 0.11 (0.12 %)
GLD $ 225.37 $ -4.12 (-1.84 %)
$ 0.701
$ 0.73
$ 0.00 x 0
$ 0.00 x 0
$ 0.69 - $ 0.73
$ 0.69 - $ 2.55
47,385,620
na
1.41B
$ 2.71
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-13-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-28-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 05-24-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 investment-advisor-says-throwing-random-darts-at-tickers-would-beat-arkk-as-cathie-woods-flagship-fund-lags-far-behind-soaring-market-how-do-they-do-it

Ram Ahluwalia of Lumida Wealth pointed to Ark's flagship ETF trading over 70% below its all-time high amid the S&P 500&...

 btig-downgrades-ginkgo-bioworks-holdings-to-sell

BTIG analyst Mark Massaro downgrades Ginkgo Bioworks Holdings (NYSE:DNA) from Neutral to Sell.

 morgan-stanley-maintains-equal-weight-on-ginkgo-bioworks-holdings-lowers-price-target-to-1

Morgan Stanley analyst Tejas Savant maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Equal-Weight and lowers the price t...

 ginkgo-bioworks-receives-notice-of-continued-listing-standard-notice-from-nyse

Ginkgo's Class A Common Stock continues to trade on the NYSEBOSTON, May 13, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, ...

 william-blair-downgrades-ginkgo-bioworks-holdings-to-underperform

William Blair analyst Matt Larew downgrades Ginkgo Bioworks Holdings (NYSE:DNA) from Market Perform to Underperform.

 ginkgo-bioworks-stock-falls-on-disappointing-q1-sales-this-trend-needs-to-change

Ginkgo Bioworks reported quarterly sales of $38 million which missed the analyst consensus estimate of $46.044 million by 17.47...

 ginkgo-bioworks-holdings-q1-2024-gaap-eps-008-beats-009-estimate-sales-38000m-miss-46044m-estimate

Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of...

 ginkgo-bioworks-holdings-q1-sales-38000m-miss-46044m-estimate

Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly sales of $38.000 million which missed the analyst consensus estimate of ...

 modalis-therapeutics-partners-with-ginkgo-bioworks-enhancing-cell-and-gene-therapy-with-crispr-gndm-technology

Modalis Joins Ginkgo's Technology Network Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) announce...

 whats-going-on-with-ginkgo-bioworks-stock

Ginkgo Bioworks announced the expansion of its strategic partnership with Novo Nordisk A/S on Wednesday under a framework agree...

 ginkgo-bioworks-reports-acquisition-of-agbiomes-platform-assets

The deal includes over 115,000 fully sequenced and isolated strains, over 500 million unique gene sequences, and relevant funct...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION